Canadian company wades into U.S. drug price debate by offering to make cheaper cancer drug
0
A small Canadian company is offering to make a prostate cancer drug that costs U.S. patients as much as $129,000 US a year for a fraction of the price but has been unable to get U.S. health authorities to override the existing patents.